Based on the Biomarin Pharmaceutical Inc stock forecast from 21 analysts, the average analyst target price for Biomarin Pharmaceutical Inc is USD 100.59 over the next 12 months. Biomarin Pharmaceutical Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Biomarin Pharmaceutical Inc is Slightly Bullish , which is based on 9 positive signals and 6 negative signals. At the last closing, Biomarin Pharmaceutical Inc’s stock price was USD 63.45. Biomarin Pharmaceutical Inc’s stock price has changed by -3.28% over the past week, -9.72% over the past month and -28.24% over the last year.
No recent analyst target price found for Biomarin Pharmaceutical Inc
No recent average analyst rating found for Biomarin Pharmaceutical Inc
Company Overview Biomarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California. Read Less
BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccha...Read More
Frequently Asked Questions About Biomarin Pharmaceutical Inc (BMRN) Stock
Based on ratings from 21 analysts Biomarin Pharmaceutical Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 34 buy, sell and 11 hold ratings.
Unfortunately we do not have enough data on BMRN's stock to indicate if its a good dividend stock.
Based on targets from 21 analysts, the average taret price for BMRN is USD 100.59 over the next 12 months. The maximum analyst target price is USD 124 while the minimum anlayst target price is USD 72.
BMRN stock's Price/Earning ratio is 40.12.
Our analysis grades BMRN stock's Price / Earning ratio at F. This means that BMRN stock's Price/Earning ratio is above 82% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this BMRN may be a overvalued for its sector.
The last closing price of BMRN's stock was USD 63.45.
The most recent market capitalization for BMRN is USD 12.69B.
Based on targets from 21 analysts, the average taret price for BMRN is projected at USD 100.59 over the next 12 months.
This means that BMRN's stock price may go up by +58.53% over the next 12 months.
We can't find any ETFs which contains Biomarin Pharmaceutical Inc's stock.
As per our most recent records Biomarin Pharmaceutical Inc has 3,401 Employees.
Biomarin Pharmaceutical Inc's registered address is 770 Lindaro Street, San Rafael, CA, United States, 94901.
You can get more information about it from Biomarin Pharmaceutical Inc's website at https://www.biomarin.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Biomarin Pharmaceutical Inc (BMRN) Stock
Based on ratings from 21 analysts Biomarin Pharmaceutical Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 34 buy, sell and 11 hold ratings.
Unfortunately we do not have enough data on BMRN's stock to indicate if its a good dividend stock.
Based on targets from 21 analysts, the average taret price for BMRN is USD 100.59 over the next 12 months. The maximum analyst target price is USD 124 while the minimum anlayst target price is USD 72.
BMRN stock's Price/Earning ratio is 40.12.
Our analysis grades BMRN stock's Price / Earning ratio at F. This means that BMRN stock's Price/Earning ratio is above 82% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this BMRN may be a overvalued for its sector.
The last closing price of BMRN's stock was USD 63.45.
The most recent market capitalization for BMRN is USD 12.69B.
Based on targets from 21 analysts, the average taret price for BMRN is projected at USD 100.59 over the next 12 months.
This means that BMRN's stock price may go up by +58.53% over the next 12 months.
We can't find any ETFs which contains Biomarin Pharmaceutical Inc's stock.
As per our most recent records Biomarin Pharmaceutical Inc has 3,401 Employees.
Biomarin Pharmaceutical Inc's registered address is 770 Lindaro Street, San Rafael, CA, United States, 94901.
You can get more information about it from Biomarin Pharmaceutical Inc's website at https://www.biomarin.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BMRN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
